NASDAQ · ELOX
Eloxx Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ELOX: Nov 10, 2026
Eloxx Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 11/10/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel- RTTNews · Oct 29, 2:04 PM EDTEloxx Gains FDA Clearance For Exaluren Phase 2 Trial In Genetic Kidney Disease(RTTNews) – Eloxx Pharmaceuticals, Inc. (ELOX) announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application for exaluren to treat nonsense-mutation autosomal dominant polycystic kidney disease (ADPKD), allowing U.S. sites to part
- Fintel · Oct 22, 6:32 AM EDTEloxx Pharmaceuticals Appoints Geno J. Germano to Board on October 19, 2026 and Announces Clinical UpdateOn October 19, 2026, the Board of Directors of Eloxx Pharmaceuticals, Inc. increased the size of the Board from five to six directors and appointed Geno J. Germano to fill the newly created vacancy. Mr. Germano will serve for a term expiring at the annual meeting of stockholders
- RTTNews · Oct 21, 2:30 AM EDTEloxx Finalizes Phase 2 ADPKD Trial Design Following FDA Feedback; Appoints New CMO(RTTNews) – Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company developing exaluren to treat rare kidney diseases, announced the finalised design of its EXPRESS phase 2 global study in nonsense-mutation autosomal dominant polycystic kidney disease (ADPK
- Fintel · Oct 15, 3:47 PM EDTCantor Fitzgerald Initiates Coverage of Eloxx Pharmaceuticals at OverweightFintel reports that on October 15, 2026, Cantor Fitzgerald initiated coverage of Eloxx Pharmaceuticals (NASDAQCM:ELOX) with an Overweight recommendation.Prior to the rating action, the pre-action close on October 14, 2026 was $12.21, a one-week price change of -17.94% from the ba
- RTTNews · Aug 24, 6:34 AM EDTBiotech Stocks At 52-Week Highs – ELOX, PRLD, ARGX, BOLD, CORT(RTTNews) – The following biotech stocks reached a 52-week high on August 21, 2026, as new trials continued enrolment and companies released positive clinical research data.
- RTTNews · Aug 21, 2:25 PM EDTTop Biotech Gainers: ELOX Clinical Progress, VOGX IPO Success, ARCT Pipeline Updates Drive Gains(RTTNews) – Today's top gainers in the biotech space include Eloxx Pharmaceuticals, following an update on its exaluren development plans; Vogenx, after its Nasdaq debut and $81.3 million IPO; Arcturus Therapeutics, following Q2 results and the return of global KOSTAIVE rights; a
- RTTNews · Aug 21, 11:17 AM EDTEloxx Q2 Loss Widens; Exaluren Phase 2b Trial Set To Begin In Q3 2026(RTTNews) – Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company developing treatments for rare kidney diseases, recently reported second-quarter 2026 financial results and provided a business update, highlighting a strengthened cash position and upcomin
- RTTNews · Aug 12, 6:29 AM EDTEloxx Pharmaceuticals, Inc. Loss At -$4.50 Mln In Q2(RTTNews) – Eloxx Pharmaceuticals, Inc. (ELOX) reported Loss for second quarter of -$4.50 million
- RTTNews · Aug 4, 4:17 AM EDTBiotech Stocks At 52-Week Highs – ANGO, ANIK, ELOX, YARW, PLSE(RTTNews) – The following biotech stocks reached a 52-week high on August 3, 2026, driven by key catalysts such as upcoming quarterly reports or the initiation of clinical trials.
- RTTNews · Jun 11, 11:54 PM EDTTop Biotech Gainers: VRXA Begins A New Chapter, ADIL Opens Wallet, PGEN, PCSA On Watch…(RTTNews) – Today's top gainers were led by Australia-based Gelteq, which develops a novel ingestible gel-based drug delivery platform; Adial Pharmaceuticals, which announced the acquisition of Azora Therapeutics as part of its pipeline expansion strategy; Precigen, which is draw
- RTTNews · Jun 9, 10:44 PM EDTTop Biotech Gainers: RGNT Walks The Talk, ELOX Returns To Relevance, ALHC Rallies, LRMR On Watch(RTTNews) – Tuesday's top biotech gainers include Regentis, which provided an update on its single-step knee repair implant; Eloxx, after getting uplisted to the Nasdaq; Alignment Healthcare, following recent corporate disclosures, including restricted stock unit (RSU) grants to
- RTTNews · Jun 9, 4:06 AM EDTEloxx Pharmaceuticals Prices $66 Million Offering And Uplisting To Nasdaq(RTTNews) – Shares of Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company developing small-molecule therapies for genetic diseases caused by nonsense mutations, fell over 31% after the company announced the pricing of a $66 million public offering and i
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Eloxx Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.